Literature DB >> 15157356

HIV type 1 that select tRNA(His) or tRNA(Lys1,2) as primers for reverse transcription exhibit different infectivities in peripheral blood mononuclear cells.

Kenda L Moore1, Barry R Kosloff, Nathan J Kelly, Richard L Kirkman, Lesley C Dupuy, Sylvia McPherson, Casey D Morrow.   

Abstract

The replication in human peripheral blood mononuclear cells (PBMC) of unique HIV-1 that select tRNA(His) or tRNA(Lys1,2) for reverse transcription was compared to the wild-type virus that uses tRNA(Lys,3). HIV-1 with only the primer-binding site (PBS) changed to be complementary to these alternative tRNAs initially replicated more slowly than the wild-type virus in PBMC, although all viruses eventually reached equivalent growth as measured by p24 antigen. Viruses with only a PBS complementary to the 3' terminal 18 nucleotides of tRNA(His) or tRNA(Lys1,2) reverted to use tRNA(Lys3). HIV-1 with mutations in the U5-PBS to allow selection of tRNA(His) and tRNA(Lys1,2) following long-term growth in SupT1 cells were also evaluated for growth and PBS stability following replication in PBMC. Although both viruses initially grew slower than wild type, they maintained a PBS complementary to the starting tRNA and did not revert to the wild-type PBS after long-term culture in PBMC. Analysis of the U5-PBS regions following long-term culture in PBMC also revealed few changes from the starting sequences. The virus that stably used tRNA(His) was less infectious than the wild type. In contrast, the virus that stably used tRNA(Lys1,2) evolved to be as infectious as wild-type virus following extended culture in PBMC. The results of these studies highlight the impact of the host cell on the tRNA primer selection process and subsequent infectivity of HIV-1.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15157356     DOI: 10.1089/088922204323048122

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  8 in total

1.  Complementation of human immunodeficiency virus type 1 replication by intracellular selection of Escherichia coli formula supplied in trans.

Authors:  Anna McCulley; Casey D Morrow
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

2.  The bipartite structure of the tRNA m1A58 methyltransferase from S. cerevisiae is conserved in humans.

Authors:  Sarah Ozanick; Annette Krecic; Joshua Andersland; James T Anderson
Journal:  RNA       Date:  2005-08       Impact factor: 4.942

3.  tRNA isoacceptor preference prior to retrovirus Gag-Pol junction links primer selection and viral translation.

Authors:  Matthew T Palmer; Richard Kirkman; Barry R Kosloff; Peter G Eipers; Casey D Morrow
Journal:  J Virol       Date:  2007-02-14       Impact factor: 5.103

4.  Impact of forced selection of tRNAs on HIV-1 replication and genome stability highlight preferences for selection of certain tRNAs.

Authors:  Na Ni; Casey D Morrow
Journal:  Virus Res       Date:  2006-10-30       Impact factor: 3.303

5.  Analysis of the replication of HIV-1 forced to use tRNAMet(i) supports a link between primer selection, translation and encapsidation.

Authors:  Uros V Djekic; Casey D Morrow
Journal:  Retrovirology       Date:  2007-02-02       Impact factor: 4.602

6.  Preferences for the selection of unique tRNA primers revealed from analysis of HIV-1 replication in peripheral blood mononuclear cells.

Authors:  Kenda L Moore-Rigdon; Barry R Kosloff; Richard L Kirkman; Casey D Morrow
Journal:  Retrovirology       Date:  2005-03-24       Impact factor: 4.602

7.  HIV-1 Subtypes and 5'LTR-Leader Sequence Variants Correlate with Seroconversion Status in Pumwani Sex Worker Cohort.

Authors:  Raghavan Sampathkumar; Joel Scott-Herridge; Binhua Liang; Joshua Kimani; Francis A Plummer; Ma Luo
Journal:  Viruses       Date:  2017-12-23       Impact factor: 5.048

8.  Low-level alternative tRNA priming of reverse transcription of HIV-1 and SIV in vivo.

Authors:  Christine M Fennessey; Celine Camus; Taina T Immonen; Carolyn Reid; Frank Maldarelli; Jeffrey D Lifson; Brandon F Keele
Journal:  Retrovirology       Date:  2019-04-04       Impact factor: 4.602

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.